Inhibikase Therapeutics, Inc. IKT
1.55 USD -0.13 (-7.74%)
At closeNov 10, 2026, 4:01 PM EST
1.55 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
1.53 Day range 1.65
1.40 52-week range 2.61
- YTD
- -24.39%
- 1 year
- -2.52%
News
benzinga.com Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5 Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.
benzinga.com Inhibikase Therapeutics Q2 EPS $(0.11), Inline Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
benzinga.com Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
benzinga.com Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.- benzinga.com Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facility For Gross Proceeds Of $50M Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
benzinga.com Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5 Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.
benzinga.com Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses…- benzinga.com Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), announced today that…
benzinga.com Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses…- benzinga.com Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4 Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6 B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8 HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program On December 19, 2025, Inhibikase Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), dated December…- benzinga.com Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4 Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Global Phase 3 Trial And Is Expected To Begin In Q1 2026 Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely,…
- benzinga.com Inhibikase Therapeutics Q3 EPS $(0.13), Inline Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Inhibikase Therapeutics Files For Mixed Shelf Of Up To $300M https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm
- benzinga.com Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses…
benzinga.com HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from Neutral to Neutral.- benzinga.com Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.90) by 28.89 percent. This is a 63.29 percent increase over…
benzinga.com This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - benzinga.com HC Wainwright & Co. Downgrades Inhibikase Therapeutics to Neutral HC Wainwright & Co. analyst Edward White downgrades Inhibikase Therapeutics (NASDAQ:IKT) from Buy to Neutral.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Inhibikase Therapeutics Q3 2024 GAAP EPS $(0.65) Misses $(0.37) Estimate Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.37) by 75.68 percent.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- benzinga.com Jefferies Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $8 Jefferies analyst Dennis Ding initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
- benzinga.com Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $5 HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $15 to $5.
- benzinga.com Dow Surges 350 Points; US Crude Oil Stocks Increase
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
- benzinga.com Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing.
- benzinga.com Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
- benzinga.com Inhibikase Therapeutics Announces Pricing Of $110M Private Placement To Advance IkT-001Pro, Into A Late-Stage Trial In Pulmonary Arterial Hypertension; Aggregate Investment Of Up To ~$275M By Healthcare-Focused Investment Funds, Led By Soleus Capital -- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital --BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase…
- benzinga.com HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $15 HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $23 to $15.